Covered recipient · General Payments record
WEIYUN Z AI
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$33,723.79
- Reported across 56 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,147.65 | 2 |
| Travel and Lodging | $1,385.87 | 3 |
| Food and Beverage | $324.74 | 5 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acrotech Biopharma Inc. | $4,654.41 | 6 |
| Gilead Sciences, Inc. | $3,050.00 | 1 |
| ADC Therapeutics America, Inc. | $108.59 | 1 |
| ABBVIE INC. | $45.26 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $25.16 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103188364 | CMS |
| ABBVIE INC. | $20.10 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103188366 | CMS |
| Acrotech Biopharma Inc. | $150.93 | 10/24/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1147104488 | CMS |
| Acrotech Biopharma Inc. | $149.24 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147104490 | CMS |
| Acrotech Biopharma Inc. | $1,158.94 | 10/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1147104492 | CMS |
| Acrotech Biopharma Inc. | $76.00 | 12/16/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1147104494 | CMS |
| Acrotech Biopharma Inc. | $21.65 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147104496 | CMS |
| Acrotech Biopharma Inc. | $3,097.65 | 12/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1147104498 | CMS |
| ADC Therapeutics America, Inc. | $108.59 | 03/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1121187400 | CMS |
| Gilead Sciences, Inc. | $3,050.00 | 11/28/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1133600161 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.